THERAPY DOSSIER · th-d4e69aaad12b

Arachidonic acid

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL15594 ↗
ChEMBL max phase: -1 / 4 (development scale, not regulatory approval)
Synonyms: Arachidonic acid; Arachidonate; cis-5,8,11,14-Eicosatetraenoic acid
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00982462 ↗NAcompleted

Extended duration long-chain PUFA (DHA and ARA) supplementation on neurological/immunological development in toddlers

Infant Development

Enrolment: 116 · Results not recorded

NCT05987384 ↗NAcompleted

The role of fatty acids (arachidonic acid) in vaccine efficacy

Rabies Vaccination Reaction

Enrolment: 45 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31953218 ↗2020Reported benefit

Arachidonic acid inhibits inflammatory responses by binding to myeloid differentiation factor-2 (MD2) and preventing MD2/toll-like receptor 4 signaling activation.

MouseEndotoxin/LPSMale

Model: Lipopolysaccharide-induced acute lung injury, with additional LPS-induced septic death and high-fat diet obesity models and cultured cardiomyocytes and macrophages

Arachidonic acid bound MD2, prevented saturated fatty acid and lipopolysaccharide-induced TLR4 activation, reduced proinflammatory cytokine induction and septic death in mice, and prevented MD2/TLR4 dimerisation, inflammatory factor induction and tissue injury in the acute lung injury and high-fat…

Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…